选择性戊二醛脱氢酶抑制剂的发现，用于癌症治疗。
Discovery of Selective Aldehyde Dehydrogenase Inhibitors for the Treatment of Cancer.
发表日期：2023 Feb 09
作者：
Robert B Kargbo
来源：
DIABETES OBESITY & METABOLISM
摘要：
ALDH1A3是19种醛脱氢酶中的一个重要成员，可以将反应性醛代谢成对应的羧酸，解毒内源和外源性醛，并参与视黄酸的生物合成。此外，ALDH1A3在不同病理过程中发挥重要的生理和毒理作用，包括2型糖尿病、肥胖症、癌症、肺动脉高压和新内膜增生。因此，抑制ALDH1A3可能为癌症、肥胖、糖尿病和心血管紊乱的患者提供新的治疗选择。2023年发表于美国化学学会。
ALDH1A3 is an important member of 19 aldehyde dehydrogenases, which metabolize reactive aldehydes to their corresponding carboxylic acids, detoxify endogenous and exogenous aldehydes, and are also involved in the biosynthesis of retinoic acid. In addition, ALDH1A3 plays important physiological and toxicological roles in different pathologies, including type II diabetes, obesity, cancer, pulmonary arterial hypertension, and neointimal hyperplasia. Consequently, inhibition of ALDH1A3 may offer new therapeutic options for patients with cancer, obesity, diabetes, and cardiovascular disorder.Published 2023 by American Chemical Society.